Bo Kruse Sells 31,371 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Free Report) CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares in the company, valued at approximately $2,545,285.39. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $12.10 on Friday. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.60 and a 1-year high of $20.90. The firm’s fifty day simple moving average is $14.28 and its 200-day simple moving average is $11.97.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. The business had revenue of $19.93 million for the quarter, compared to analyst estimates of $22.06 million. On average, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in YMAB. Boston Partners bought a new stake in Y-mAbs Therapeutics during the first quarter worth approximately $556,000. Caxton Associates LP bought a new position in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $306,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after buying an additional 1,657 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Y-mAbs Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after buying an additional 3,340 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a research report on Monday, February 12th. HC Wainwright lifted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Canaccord Genuity Group upped their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, BMO Capital Markets lifted their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $17.33.

Get Our Latest Research Report on YMAB

Y-mAbs Therapeutics Company Profile

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Featured Articles

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.